Milverine was studied as an antibacterial agent. Information about the current use of this drug is not available.

Neboglamine is a functional modulator of the glycine site on the N-methyl-D-aspartate (NMDA) receptor. Neboglamine appeared to promote neuronal growth as measured by expression of Fos-like immunoreactivity, particularly in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus. Neboglamine behaves as a potential antipsychotic. Neboglamine is in phase II clinical trials by Rottapharm for the treatment of schizophrenia and cocaine abuse.

Mecrylate (metyl 2-cyanoacrylate) ) is a clear, colorless liquid with a strong, acrid odor. In contact with hydroxide ions (liquids like blood or water, air humidity), the cyanoacrylates form long, strong and waterproof chains in an exothermic reaction. The resulting polymer leads to a stable adhesive bond. It may be used as tissue adhesive in surgery. Mecrylate is the first generation short-chain cyanoacrylate, it turned out to be histotoxic and caused distinct foreign-body reactions.

Maraciclatide (NC100692 or diamine dioxime-Lys-Cys-Arg-Gly-Asp-Cyc-Phe-Cys-polyethylene glycol) is a cyclic peptide that contains an RGD tripeptide sequence held in a specific conformation by a disulphide and one thioether bridge. The ε-amino group of the lysine residue serves as an attachment point for the technetium chelator and the C-terminal end modified with a short polyethylene glycol unit. Cyclic RGD peptides such as this have a high affinity towards vitronectin receptors. Maraciclatide radiolabelled with technetium 99m (99mTc) is being developed as an in vivo diagnostic marker of vitronectin integrin receptor expression.

Lunacalcipol (CTA-018 or MT-2832) is a vitamin D analog having a dual mechanism of action. It inhibits CYP24A1 and induced VDR expression. It was being developed for the treatment of clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease. Lunacalcipol development has been discontinued.

LAURIXAMINE is a fungicide. It is an antibacterial, ophthalmologic agent.

Eterobarb (Antilon) is a barbiturate derivative. It is an effective anticonvulsant as demonstrated in animal and clinical studies. Eterobarb possesses a unique and clinically intriguing feature-at therapeutically effective blood levels, the hypnotic side effects usually associated with barbiturates appear absent. Though effective against both electrically and chemically induced seizures in mice and rats, virtually no hypnotic effects were noted except at lethal doses. Double-blind cross-over studies have confirmed the anticonvulsant efficacy of eterobarb and several phase II and phase Ill studies show eterobarb to be an effective anticonvulsant with less hypnotic activity when compared with phenobarbital. Eterobarb had been NDA filed for the treatment of epilepsy in the US, UK, Switzerland and Canada. However, this research has been discontinued. The compound was originated by Colgate Palmolive, then licensed to MacroChem.

Etazolate (EHT-0202) is a selective, positive GABAA receptor modulator has completed phase II clinical trials in patients with Alzheimer's disease. It is also a selective phosphodiesterase-4 inhibitor that is specific for cAMP. Etazolate showed anxiolytic and antidepressant activity and could be useful in managing post-traumatic stress disorder.

Esuprone (LU 43839) is a monoamine oxidase type A inhibitor. Esuprone proved to be an effective anticonvulsant in the kindling model. Esuprone was undergoing phase II clinical trials with Knoll (BASF Pharma) in Germany as an antidepressant.